NRX-101 Archives - Page 2 of 3 - NRx Pharmaceuticals

Nov. 20, 2023

Jane King, NASDAQ MarketSite interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals

Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.

Jan. 19, 2023

NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.

Jan. 3, 2023

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality – First Clinical Site Contracted

NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.

Nov. 9, 2022

NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).

Aug. 2, 2022

CEO Update on Recent Findings Related to Serotonin and its Role in Depression

In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.

Aug. 1, 2022

Scientific Update from NRx Pharmaceuticals Chief Scientist, Jonathan Javitt, MD, MPH

In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.

May. 12, 2022

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

NRx Pharmaceuticals enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality.

Dec. 29, 2021

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approved Therapies

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19.

NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results

RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial […]

Cookie	Duration	Description
_wpfuuid	11 years	This cookie is used by the WPForms WordPress plugin. The cookie is used to allows the paid version of the plugin to connect entries by the same user and is used for some additional features like the Form Abandonment addon.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
nlbi_1816097	session	A load balancing cookie set to ensure requests by a client are sent to the same origin server.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
visid_incap_1816097	1 year	SiteLock sets this cookie to provide cloud-based website security services.

Cookie	Duration	Description
_jsuid	1 year	This cookie contains random number which is generated when a visitor visits the website for the first time. This cookie is used to identify the new visitors to the website.
cluid	1 year	This cookie is used for websites which is having multiple domains to identify the same visitor across multiple domains.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
mo_has_visited	11 years	This cookie is used for setting an unique ID for the visitor which helps to get the accurate number of specific visitor on the website.
mo_is_new	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.
mo_page_views_counter	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.

Cookie	Duration	Description
c	6 months 2 days	This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services.
uuid	1 year 27 days	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
incap_ses_1371_1816097	session	No description
unpoco_101344884	1 day	No description